Pluviaendo Visuals Pluviaendo Visuals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of EpiBiologics.

    Client Virtual Booth

    EPIBIOLOGICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    EpiBiologics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1900 Alameda de las Pulgas Suite 250 San Mateo, CA 94403
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.epibiologics.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million

    Details:

    The net financing will enable EpiBiologics to expand and validate the platform, advance its pipeline of next-generation protein degradation platform.


    Lead Product(s): Bispecific Antibody

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Digitalis Ventures

    Deal Size: $73.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing July 20, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform

    Details:

    The funds will be used in EpiTAC platform which expands the targeted protein degradation landscape to the extracellular space, enabling the company to target both membrane proteins and secreted proteins through the use of genetically encoded bifunctional antibodies.


    Lead Product(s): Bifunctional Antibody

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Mubadala Capital

    Deal Size: $50.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing March 22, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    chemwerth-inc-m-2024-06-03

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search